Adia Nutrition has appointed Dr. Richard Edwards as its second Medical Director, joining Dr. Monica Sher to form a diverse and highly experienced board. This strategic move signifies the company’s commitment to providing exceptional care and advancing innovative aHSCT treatments for patients with Multiple Sclerosis (MS).
The global aplastic anemia market is expected to experience significant growth over the next decade, driven by a surge in research activities, the introduction of novel treatment options, and an increasing focus on improving patient outcomes. This market is projected to reach US$ 10.8 billion by 2034, with a CAGR of 4.3% from 2024 to 2034.
